Systemic Inflammation Score Predicts Postoperative Prognosis of Patients with Clear-cell Renal Cell Carcinoma

Overview

Journal Br J Cancer

Specialty Oncology

Date 2015 Jul 3

PMID 26135896

Citations 100

Authors

Y Chang

H An

L Xu

Y Zhu

Y Yang

Z Lin

J Xu

Affiliations

Soon will be listed here.

Abstract

Background: Growing evidence indicates that inflammation has a crucial role in the development and progression of cancer. We developed a novel systemic inflammation score (SIS) based on preoperative serum albumin and lymphocyte-to-monocyte ratio (LMR), and examined its prognostic value for patients with clear-cell renal cell carcinoma (ccRCC) after surgery.

Methods: The study comprised 441 ccRCC patients undergoing nephrectomy between 2008 and 2009 in a single centre. The SIS was developed and its associations with clinicopathological features and overall survival (OS) were evaluated.

Results: The SIS consisted of serum albumin and LMR that were both retained as independent indicators adjusting for other haematological and laboratory markers of systemic inflammation responses and traditional clinicopathological features. A high SIS was significantly associated with aggressive tumour behaviours and served as an independent prognostic factor of reduced OS. Furthermore, the SIS could significantly stratify patient prognosis in different tumour stages and Mayo Clinic stage, size, grade and necrosis scores. Incorporation of the SIS into a prognostic model including TNM stage, Fuhrman grade and lymphovascular invasion generated a nomogram, which predicted accurately 3- and 5-year survival for ccRCC patients.

Conclusions: The SIS as a potentially powerful prognostic biomarker might improve traditional clinicopathological analysis to refine clinical outcome prediction for ccRCC patients after surgery.

Citing Articles

Preoperative predictors of concurrent endometrial carcinoma in patients with endometrial intraepithelial neoplasia: the role of HALP score and other inflammatory markers.

Aytekin O, Karagoz C, Goktas E, Tokalioglu A, Tiryaki Guner G, Ozkaya Ucar Y J Turk Ger Gynecol Assoc. 2025; 26(1):34-40.

PMID: 40077970 PMC: 11905214. DOI: 10.4274/jtgga.galenos.2025.2024-12-5.

Combined inflammation-related biomarkers and clinicopathological features for the prognosis of stage II/III colorectal cancer by machine learning.

Liang L, Xu N, Ding L, Li X, Jiang C, Zhang J BMC Cancer. 2024; 24(1):1548.

PMID: 39696042 PMC: 11656819. DOI: 10.1186/s12885-024-13331-1.

Tumor microbiota of renal cell carcinoma affects clinical prognosis by influencing the tumor immune microenvironment.

Xu H, Leng J, Liu F, Chen T, Qu J, Yang Y Heliyon. 2024; 10(19):e38310.

PMID: 39397906 PMC: 11470785. DOI: 10.1016/j.heliyon.2024.e38310.

Same Organ, Two Cancers: Complete Analysis of Renal Cell Carcinomas and Upper Tract Urothelial Carcinomas.

Vamesu S, Ursica O, Milea S, Deacu M, Aschie M, Mitroi A Medicina (Kaunas). 2024; 60(7).

PMID: 39064555 PMC: 11279004. DOI: 10.3390/medicina60071126.

Research on molecular characteristics of ADME-related genes in kidney renal clear cell carcinoma.

Zhang H, Huang W, Chen M, Liu Y, Yan B, Mou S Sci Rep. 2024; 14(1):16834.

PMID: 39039118 PMC: 11263354. DOI: 10.1038/s41598-024-67516-6.

References

Frank I, Blute M, Cheville J, Lohse C, Weaver A, Zincke H . An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002; 168(6):2395-400. DOI: 10.1016/S0022-5347(05)64153-5. View

Dunn G, Old L, Schreiber R . The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004; 21(2):137-48. DOI: 10.1016/j.immuni.2004.07.017. View

Edge S, Compton C . The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17(6):1471-4. DOI: 10.1245/s10434-010-0985-4. View

Qian B, Pollard J . Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141(1):39-51. PMC: 4994190. DOI: 10.1016/j.cell.2010.03.014. View

Hutterer G, Stoeckigt C, Stojakovic T, Jesche J, Eberhard K, Pummer K . Low preoperative lymphocyte-monocyte ratio (LMR) represents a potentially poor prognostic factor in nonmetastatic clear cell renal cell carcinoma. Urol Oncol. 2014; 32(7):1041-8. DOI: 10.1016/j.urolonc.2014.04.001. View

Hermanns T, Bhindi B, Wei Y, Yu J, Noon A, Richard P . Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Br J Cancer. 2014; 111(3):444-51. PMC: 4119979. DOI: 10.1038/bjc.2014.305. View

Krenn-Pilko S, Langsenlehner U, Thurner E, Stojakovic T, Pichler M, Gerger A . The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br J Cancer. 2014; 110(10):2524-30. PMC: 4021515. DOI: 10.1038/bjc.2014.163. View

Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Friesenbichler J . The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer. 2013; 135(2):362-70. DOI: 10.1002/ijc.28677. View

Pichler M, Hutterer G, Stoeckigt C, Chromecki T, Stojakovic T, Golbeck S . Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer. 2013; 108(4):901-7. PMC: 3590665. DOI: 10.1038/bjc.2013.28. View

10.

McMillan D . The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2012; 39(5):534-40. DOI: 10.1016/j.ctrv.2012.08.003. View

11.

Fox P, Hudson M, Brown C, Lord S, Gebski V, de Souza P . Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. Br J Cancer. 2013; 109(1):147-53. PMC: 3708579. DOI: 10.1038/bjc.2013.300. View

12.

Shariat S, Xylinas E . Biomarkers in personalised treatment of renal-cell carcinoma. Lancet Oncol. 2012; 13(8):751-2. DOI: 10.1016/S1470-2045(12)70292-9. View

13.

Ljungberg B, Campbell S, Choi H, Cho H, Jacqmin D, Lee J . The epidemiology of renal cell carcinoma. Eur Urol. 2011; 60(4):615-21. DOI: 10.1016/j.eururo.2011.06.049. View

14.

Morgan T, Tang D, Stratton K, Barocas D, Anderson C, Gregg J . Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol. 2011; 59(6):923-8. PMC: 3085569. DOI: 10.1016/j.eururo.2011.01.034. View

15.

Gupta D, Lis C . Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010; 9:69. PMC: 3019132. DOI: 10.1186/1475-2891-9-69. View

16.

Chechlinska M, Kowalewska M, Nowak R . Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat Rev Cancer. 2010; 10(1):2-3. DOI: 10.1038/nrc2782. View

17.

McMillan D . Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009; 12(3):223-6. DOI: 10.1097/MCO.0b013e32832a7902. View

18.

Mantovani A . Cancer: Inflaming metastasis. Nature. 2009; 457(7225):36-7. DOI: 10.1038/457036b. View

19.

McMillan D . An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 2008; 67(3):257-62. DOI: 10.1017/S0029665108007131. View

20.

Mantovani A, Allavena P, Sica A, Balkwill F . Cancer-related inflammation. Nature. 2008; 454(7203):436-44. DOI: 10.1038/nature07205. View